Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Fresenius Kabi Austria GmbH has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 3 examiners and 3 art units, indicating distinct examination paths for each pending action.
OLSEN, KAELEIGH ELIZABETH is the busiest examiner, with 1 pending matter. Counsel should maintain separate matter strategies and monitor each examiner record independently.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KWON, YONG SOK | 1 | 24.6% | +42.7% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705423 | PHYTONADIONE FOR PARENTERAL ADMINISTRATION | KWON, YONG SOK | — |
| 18572334 | AQUEOUS, ROOM-TEMPERATURE STABLE ROCURONIUM COMPOSITION | O DELL, DAVID K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705423 | PHYTONADIONE FOR PARENTERAL ADMINISTRATION | KWON, YONG SOK | — |
| 18572334 | AQUEOUS, ROOM-TEMPERATURE STABLE ROCURONIUM COMPOSITION | O DELL, DAVID K | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705423 | PHYTONADIONE FOR PARENTERAL ADMINISTRATION | KWON, YONG SOK | 1613 | §103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18572334 | AQUEOUS, ROOM-TEMPERATURE STABLE ROCURONIUM COMPOSITION | O DELL, DAVID K | 1621 | §102§103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFresenius Kabi Austria GmbH has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Yong Sok Kwon has the most, with 1 of Fresenius Kabi Austria GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
